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Abstract 
 
Genetic analysis of the biosynthesis of pharmaceutically important dihydroergot alkaloids by 
heterologous expression of Claviceps gigantea genes in the fungus Neosartorya fumigata 
 
Ergot alkaloids are a family of secondary metabolites produced by several species of fungi.  The 
structural similarities of ergot alkaloids to neurotransmitters give them the ability to help treat 
several neurological and cognitive diseases, such as dementia, Alzheimer’s and Parkinson’s 
disease.  These pharmaceuticals are currently being synthesized from more complex ergot 
alkaloids, however they would be more efficiently synthesized from dihydroergot alkaloids. 
Understanding the genes involved in the synthesis of dihydroergot alkaloids, such as 
dihydrolysergol and dihydrolysergic acid, and elucidating their pathways will be beneficial.  The 
Mexican maize ergot pathogen Claviceps gigantea has been reported to produce dihydrolysergol, 
which is an oxidized product of the precursor ergot alkaloid festuclavine.  Due to the discovery of 
an ergot alkaloid synthesis gene, cloA, catalyzing multiple oxidations on a similar substrate, it was 
hypothesized that expression of C. gigantea cloA in a festuclavine-accumulating mutant of the 
model fungus Neosartorya fumigata would yield dihydrolysergol.  HPLC and LC-MS analyses of 
the cloA transformed strains, demonstrated that the modified strain produced dihydrolysergic acid, 
the fully oxidized product of dihydrolysergol. Since dihydrolysergol was expected to be the 
pathway end product of C. gigantea, the genomic sequence data was analyzed and extracts of field-
grown C. gigantea.  The natural alkaloid analysis results supported the finding that dihydrolysergic 
acid is the end product of the C. gigantea pathway, rather than dihydrolysergol.  C. gigantea is the 
first organism demonstrated to produce the pharmaceutically important compound dihydrolysergic 
acid as its pathway end product and heterologous expression of its cloA gene may serve as the 
basis of a more efficient approach to production of DHLA for pharmaceutical purposes.  
Additional attempts to increase the yield of dihydrolysergic acid in our modified strain, such as 
removal of introns, expression from an alternative promoter, and coexpression with an additional 
ergot alkaloid synthesis gene, easA, were conducted. The removal of introns and the alternative 
promoter had no significant effect on the yield of dihydrolysergic acid compared to the original 
cloA transformants in ANOVA (p = 0.58 and p = 0.76). However, the mutants expressing cloA-
easA had conversion rates two-fold higher than the mutants expressing cloA (p = 0.01).  The data 
illustrate that CloA of C. gigantea catalyzes a six-electron oxidation of festuclavine to 
dihydrolysergic acid.
iii 
 
 
 
Table of Contents 
Abstract ........................................................................................................................................... ii 
Literature Review/Introduction ....................................................................................................... 1 
Ergot Alkaloids ........................................................................................................................... 1 
Ergot Alkaloid Pathway .............................................................................................................. 3 
Claviceps gigantea ...................................................................................................................... 8 
Rationale and Hypothesis ............................................................................................................... 9 
Materials and Methods .................................................................................................................. 10 
C. gigantea gene cluster ............................................................................................................ 10 
C. gigantea natural alkaloid analysis ........................................................................................ 10 
Resequencing of pseudogene lpsA from C. gigantea ................................................................ 11 
Preparation of transformation constructs .................................................................................. 11 
C. gigantea cloA construct ......................................................................................................... 12 
C. gigantea intron free cloA construct ...................................................................................... 13 
C. gigantea gpdA promoter construct ....................................................................................... 14 
C. gigantea easA-cloA construct ............................................................................................... 15 
Fungal Transformation .............................................................................................................. 17 
mRNA analysis ......................................................................................................................... 18 
Agroclavine feeding study ........................................................................................................ 19 
Compartmentalization study ..................................................................................................... 19 
HPLC and LC-MS analyses of the transformants ..................................................................... 20 
Results ........................................................................................................................................... 21 
Function of C. gigantea cloA. ................................................................................................... 21 
Analysis of the natural ergot alkaloid profile of C. gigantea. ................................................... 22 
Characterization of C. gigantea eas gene cluster. ..................................................................... 24 
Approaches to increase production of dihydrolysergic acid. .................................................... 25 
Substrate specificity of C. gigantea CloA. ................................................................................ 31 
Discussion ..................................................................................................................................... 32 
Acknowledgements ....................................................................................................................... 36 
References ..................................................................................................................................... 37 
 
1 
 
 
 
Literature Review/Introduction 
Ergot Alkaloids 
Ergot is a fungal infection caused by Claviceps species that affect rye, wheat, corn, and 
several other monocot plants. Ergot alkaloids are agriculturally and pharmaceutically important, 
though many Claviceps species produce ergot alkaloids, which have caused mass poisonings, 
called ergotism, as a result of accumulations of these alkaloids in grain crops. Ergot alkaloids also 
have caused reduced weight gain and fitness in grazing animals as a result of their accumulation 
in related endophytic fungi (Epichloë species) that colonize forage grasses (Robinson and 
Panaccione, 2014). However, in 1918, Sandoz marketed ergot alkaloids as bulk pharmaceutical 
chemicals, when it was discovered they had clinical uses (Schiff, 2006). Many fungi in the genus 
Claviceps (in the family Clavicipitaceae) produce a variety of ergot alkaloids, including clavines 
and lysergic acid derivatives. A different set of ergot alkaloids are produced by the distantly related 
fungus Neosartorya fumigata, from the family Trichocomaceae. Over 80 distinct types of ergot 
alkaloids have been isolated, mainly from the genus Claviceps (Schiff, 2006).  
Ergot alkaloids are a family of secondary metabolites and represent the largest group of 
nitrogenous fungal metabolites in nature (Schiff, 2006). Ergot alkaloids are limited to a narrow set 
of species, such as those found in the families Clavicipitaceae and Trichocomaceae, so they have 
a limited distribution in nature.  Ergot alkaloids play a role in plant defense, because they have 
harmful effects on vertebrate and invertebrate herbivores (Panaccione et al., 2006; Potter et al., 
2008).  
Ergot alkaloids are small molecules that are heavily derivatized from the amino acid 
tryptophan. Tryptophan is an indole derivative and is a precursor to the neurotransmitter serotonin. 
Ergot alkaloids also have structural similarities to the neurotransmitters dopamine, adrenaline, and 
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noradrenaline, making them useful pharmaceuticals. Ergot alkaloids’ pharmaceutical effects are 
the result of their agonism or antagonism at serotonergic, dopaminergic, and adrenergic receptors 
in the central nervous system, as well as at adrenergic receptors in blood vessels (Schiff, 2006; 
Gerhards et al., 2014). This allows ergot alkaloids to be used clinically to treat several neurological 
and cognitive diseases, such as migraines, dementia, Alzheimer’s, and Hyperprolactinemia 
(Morren and Galvez-Jimenez, 2010; Baskys and Hou, 2007; Winblad et al., 2007; Kerr et al., 2010; 
Table 1). Several important pharmaceuticals are semisynthetic derivatives of dihydrolysergic acid 
or its intermediate dihydroelymoclavine (i.e. dihydrolysergol), which are ergot alkaloids rarely 
encountered in nature; therefore elucidating their biosynthetic route would be beneficial (Bilovol 
and Panaccione, 2016; Fig. 1; Table 1).  
 
 
Figure 1: Structures of the dihydroergot alkaloids dihydrolysergol and dihydrolysergic acid compared to 
their potential pharmaceutical products. Green arrows indicate the pharmaceuticals dihydrolysergol is 
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capable of producing and blue arrows indicate the pharmaceuticals dihydrolysergic acid is capable of 
producing. 
Table 1: Ergot Alkaloids and their Pharmaceutical Uses 
Ergot 
Alkaloid 
 
Brand 
Name 
Clinical use(s) Current 
semisynthetic 
derivation 
Efficient 
semisynthetic 
derivation 
Nicergoline 
 
Sermion Senile dementia, 
Alzheimer’s, 
cerebral thrombosis 
From LA via other 
ergot alkaloids 
From DHlysergol, 
lysergol, or DHLA 
Cabergoline 
 
Caberlin, 
Dostinex 
Hyperprolactinemia
, pituitary 
prolactinomas 
From LA via other 
ergot alkaloids 
From DHLA 
Pergolide 
 
Permax Parkinson’s 
(elsewhere, 
withdrawn in USA, 
2007) 
From LA via other 
ergot alkaloids 
From DHlysergol 
Ergoloid 
mesylates 
 
Hydergine Senile dementia From ergopeptines or 
LA via other ergot 
alkaloids 
From 
DHergopeptines or 
DHLA 
DHergotami
ne 
 
DHE 45, 
Migranal 
Migraines From ergotamine or 
LA via other ergot 
alkaloids 
From DHergotamine 
or DHLA 
Abbreviation: LA- lysergic acid, DH – dihydro, DHLA – dihyrdrolysergic acid 
Ergot Alkaloid Pathway 
Individual species in two major fungal families, Clavicipitaceae and Trichocomaceae, are 
known to produce ergot alkaloids. All fungi that produce ergot alkaloids share the same early 
biosynthetic steps that lead to the formation of the ergoline ring structure, before diverging into 
specific ergot alkaloid lineages (Coyle et al., 2014). For the production of all ergot alkaloids, the 
ergot alkaloid synthesis (eas) genes that are involved are all found in clusters in each genome of 
the producing organism. No gene that is critical to the production of ergot alkaloids is located 
outside of an eas gene cluster (Bilovol and Panaccione, 2016). Modifications to the ergoline rings 
by enzymes in the eas gene cluster results in chemical products that are used as the basis for 
pharmaceutical drugs. Gene clusters from several fungi have been elucidated through genome 
mining, knock-out experiments, and overexpression experiments (Gerhards et al., 2014).  
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The ergot alkaloid pathway in both Claviceps species and N. fumigata is initiated by the 
prenylation of tryptophan, which is catalyzed by dimethylallyltryptophan synthase encoded by the 
gene dmaW (Fig. 2). Coyle et al. (2010) demonstrated that chanoclavine-I-aldehyde is the last 
shared intermediate in the ergot alkaloid pathway for Claviceps and N. fumigata (Fig. 2). The 
branch point between these pathways occurs during the D ring closure, as a result of the products 
of different alleles of easA have functional differences. EasA is an oxidoreductase of the ‘old 
yellow enzyme’ class, which reduces double bonds that are conjugated to either aldehydes or 
ketones. In the ergot alkaloid pathway, EasA reduces the double bond conjugated to the aldehyde 
group of chanoclavine-I-aldehyde, which allows for ring closure by Schiff base formation (Coyle 
et al., 2010). In N. fumigata, the 8,9 double bond in chanoclavine-I-aldehyde is reduced by the 
reductase form of EasA (Fig. 2). The derived iminium ion is further reduced by EasG to form 
festuclavine, which can be acetylated at carbon 2 and/or prenylated at carbon 9 to produce 
fumigaclavine derivatives (Fig. 2) (Wallwey et al., 2010; Cheng et al., 2010). In most Claviceps 
species, an isomerase form of EasA transiently reduces chanoclavine-I-aldehyde before re-
oxidizing it to produce the 8,9 unsaturated agroclavine (Fig. 2) (Coyle et al., 2010). In C. purpurea 
and Epichloë species agroclavine is oxidized to produce elymoclavine, elymoclavine is further 
oxidized and isomerized to produce lysergic acid, and lysergic acid is assimilated into ergopeptines 
and/or lysergic acid amides (Fig. 2) (Robinson and Panaccione, 2014). As a result of this major 
difference, fungi in the family Clavicipitaceae synthesize lysergic acid derivatives, in which 
carbons 9 and 10 in the D ring of the ergoline ring structure are unsaturated and carbon 17 is 
oxidized (Fig. 2) (Panaccione et al., 2014; Schardl et al., 2006; Lorenz et al., 2009). Fungi in the 
family Trichocomaceae synthesize clavine derivatives, in which carbons 9 and 10 in the D ring are 
fully saturated and carbon 17 remains as a methyl group (Fig. 2) (Panaccione et al., 2012; Wallwey 
and Li, 2011). Lysergic acid derivatives are produced exclusively by the family Clavicipitaceae 
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and not by model organisms, like N. fumigata, in which their modification might be facilitated 
(Robinson and Panaccione 2014). 
Coyle et al. (2010) also created two mutant strains of N. fumigata. The first was an easA 
knockout strain, which was created by integrating pAFOYE1, along with the hygromycin 
resistance plasmid pMOcosX, into easA (reductase) in order to disrupt its function. The disruption 
construct, pAFOYE1, contained a 595 bp fragment from the 1,131 bp coding sequence of easA 
from N. fumigata ligated into the T/A overlap vector pCR2.1. This mutant strains pathway ended 
at chanoclavine-I-aldehyde, which is the last common intermediate between the fumigaclavine C 
and lysergic acid pathways. This strain was also beneficial, because it allowed Coyle et al. (2010) 
to investigate the functions of easA isomerase compared to easA reductase. By cotransforming 
easA isomerase from C. purpurea along with pBC-phleo, a phleomycin resistance plasmid, into 
the easA KO strain, they were able to modify the ergot alkaloid profile. Instead of detecting the 
usual alkaloids such as festuclavine and fumigaclavines A,B, and C, they detected setoclavine, 
isosetoclavine, and large amounts of agroclavine (Coyle et al. 2010). 
Robinson and Panaccione (2014) engineered a strain of N. fumigata to transform 
agroclavine into lysergic acid (Fig. 2). This was done by using an N. fumigata easA knockout strain 
as host fungus, so that the pathway stopped at chanoclavine-I-aldehyde. A construct containing 
easA (isomerase) and a second gene, cloA, both from an Epichloë species, was transformed into 
the N. fumigata easA knockout strain, so that the EasA isomerase converted chanoclavine-I-
aldehyde into agroclavine and CloA converted agroclavine into lysergic acid. The gene cloA, 
which stands for clavine oxidase, was required for complete oxidation of carbon 17 of both 
agroclavine and elymoclavine during the synthesis of lysergic acid (Fig. 2). The gene encodes a 
P450 monooxygenase and is only found in fungi that produce lysergic-acid derivatives (Robinson 
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and Panaccione, 2014). It was concluded that CloA catalyzes a six-electron oxidation of 
agroclavine to lysergic acid and that either CloA or EasA isomerizes the 8,9 double bond in the D 
ring to the 9,10 position. CloA had multiple catalytic activities, including a two-electron oxidation 
of agroclavine to elymoclavine and an additional two sets of two-electron oxidations to convert 
elymoclavine to lysergic acid. The lack of detectable elymoclavine in the extracts of the developed 
strain indicated that CloA could execute successive oxidations and an isomerization without 
releasing the substrate (Robinson and Panaccione, 2014). 
Two species from Clavicipitaceae, Claviceps gigantea and Claviceps africana, have been 
reported to produce dihydroergot alkaloids, however the genes involved in their biosynthetic 
pathways have not been investigated. Dihydroergot alkaloids differ from lysergic acid-derived 
alkaloids due to carbons 9 and 10 being saturated and carbon 17 being oxidized (Bilovol and 
Panaccione, 2016), giving them different, unique pharmaceutical properties. These species are 
similar to N. fumigata, due to chanoclavine-I-aldehyde being reduced by EasA reductase to 
produce festuclavine. Barrow et al. (1974) investigated the dihydroergot alkaloid pathway through 
an approach based on feeding labeled precursors to the fungus Claviceps africana. They showed 
that the dihydroergot alkaloid pathway in C. africana and by extension C. gigantea proceeded 
from festuclavine to dihydroelymoclavine to dihydrolysergic acid to dihydroergosine (Fig. 2). It 
is predicted that festuclavine could be transformed into dihydroelymoclavine then dihydrolysergic 
acid by oxidizing carbon 17, analogous to the agroclavine to lysergic acid pathway. 
Dihydrolysergic acid derivatives are also solely produced by the family Clavicipitaceae and not 
by model organisms, such as N. fumigata, in which their modification may be facilitated (Robinson 
and Panaccione, 2014). Many of the genes that are necessary in the biosynthesis of the lysergic 
acid-derived ergot alkaloids have been characterized, but the genes that are necessary in the 
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synthesis of dihydroergot alkaloids have yet to be studied (Bilovol and Panaccione, 2016). Among 
the genes in the eas cluster, cloA is the reasonable candidate to conduct the first oxidation of carbon 
17 of festuclavine to produce dihydroelymoclavine, due to the discovery of its catalytic functions 
on a similar substrate, agroclavine (Robinson and Panaccione 2014). 
 
Figure 2: Lysergic acid pathway (left; Robinson and Panaccione, 2014), predicted dihydroergot alkaloid 
pathway (middle; Barrow et al., 1974), and fumigaclavine pathway (right; Bilovol and Panaccione, 2016). 
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Both intermediates and products are shown along with the enzymes responsible (indicated next to arrows). 
Double arrows express the omission of one or more intermediates. The ergoline ring structure is shown in 
the top right for reference to descriptions in text. 
 
In N. fumigata, festuclavine is transformed into fumigaclavines through the hydroxylation 
and acetylation of carbon 2 and/or the prenylation of carbon 9 (Fig. 2). The gene easM encodes 
for the festuclavine-hydroxylating enzyme, which hydroxylates festuclavine into fumigaclavine B 
(Fig. 2).  Bilovol and Panaccione (2016) prepared an easM knockout strain of N. fumigata, so the 
ergot alkaloid pathway stops at and accumulates large quantities of festuclavine (30.9 
amol/conidium). The strain was derived by replacing part of the easM coding sequence with a 
hygromycin resistance gene, in order to disrupt the gene’s function. This development is 
beneficial, because festuclavine is the last common intermediate in both the fumigaclavine branch 
in N. fumigata and in the dihydroergot alkaloid pathway in certain Claviceps species. This mutant 
strain will be useful for studying genes important in the synthesis of dihydroergot alkaloids, since 
festuclavine is the precursor to dihydroergot alkaloids (Bilovol and Panaccione 2016). The 
candidate gene, cloA, was tested through expression in an N. fumigata easM knockout (easM KO) 
strain and an N. fumigata easA knockout (easA KO) strain. 
Claviceps gigantea 
A new species of Claviceps was described in the 1960s (Fuentes et al. 1964). The fungus 
grew on maize and was reported due to the toxic effects it caused when ingested. The fungus is 
recognized by the large, soft sclerotia that replace the kernels on maize. Large numbers of 
microconidia occur on the sclerotia, and they were isolated to prove they were the etiological agent 
(Ullstrup, 1973). The sclerotia produced the typical stipe and stroma of other Claviceps species, 
however, they were much larger than any other described species, so the new species Claviceps 
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gigantea was described. C. gigantea has a very limited geographical distribution and is only found 
at high altitudes in Mexico, where the climate is cool and humid (Ullstrup, 1973). 
C. gigantea was studied for ergot alkaloids in Agurell and Ramstad’s work in 1965. 
Festuclavine and dihydroelymoclavine (synonym dihydrolysergol) were two alkaloids isolated 
from the sclerotia of the fungus. This was the first time dihydrolysergol was isolated from a natural 
source, and it is relevant because dihydrolysergol is closely related to dihydrolysergic acid.  For 
example, it had previously been chemically cleaved from dihydrolysergic acid methyl ester 
(Agurell and Ramstad, 1965). Overall, most species of Claviceps produce derivatives of lysergic 
acid. However, it is believed that C. gigantea is capable of producing other dihydroergot alkaloids, 
based on the isolation of dihydrolysergol from the fungus. This fungus may be an appropriate 
genetic resource for studies on dihydroergot alkaloid biosynthesis. 
Rationale and Hypothesis 
Though many steps in the ergot alkaloid pathways have been clarified, the dihydroergot 
alkaloid pathway remains to be elucidated. As a result, dihydroelymoclavine and dihydrolysergic 
acid used for pharmaceutical purposes must be chemically modified from more complex, naturally 
occurring ergot alkaloids. The easM knockout strain of N. fumigata created by Bilovol and 
Panaccione (2016) is the ideal host for my planned experiment, since it accumulates high amounts 
of festuclavine, which is the precursor to dihydroergot alkaloids (Barrow et al., 1974). 
Additionally, the discovery of the multiple catalytic functions of the enzyme CloA make it a 
reasonable candidate to oxidize carbon 17 of festuclavine to transform it into dihydroelymoclavine 
or dihydrolysergic acid. I intend to test the gene cloA from the fungus C. gigantea, due to this 
fungus being reported to produce dihydroelymoclavine. Therefore, it is hypothesized that cloA 
from C. gigantea introduced into the easM knockout strain of N. fumigata will result in the 
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oxidation of festuclavine into dihydroelymoclavine or perhaps dihydrolysergic acid (Fig. 2). The 
objective of this project is to modify a strain of N. fumigata to produce dihydroelymoclavine or 
dihydrolysergic acid as its final product. This was done by transforming the gene cloA from C. 
gigantea into the festuclavine-accumulating easM knockout strain of N. fumigata. 
Materials and Methods 
C. gigantea gene cluster 
 The C. gigantea eas gene cluster (Figure 9B) was identified by querying the genome’s 
sequence with individual eas genes from other Claviceps species. Additional eas genes were 
identified by blastx comparisons to the nonredundant nucleotide database at NCBI. 
C. gigantea natural alkaloid analysis 
C. gigantea sclerotia samples were obtained from Montecillo, Mexico (Fig. 3). The head 
of the sclerotia was pulverized with 10 glass beads (3-mm diameter) in 300 µL of HPLC-grade 
methanol by a Fastprep 120 (Bio101, Carlsbad, CA) for 30s at 6 m/s. Alkaloids were extracted for 
1 hour, then the sample was pelleted by centrifugation and 20 µL of supernatant was analyzed by 
HPLC with fluorescence detection. 
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Figure 3: Image of three C. gigantea sclerotia samples analyzed for natural alkaloid production. The top 
row are the sclerotia heads, which were analyzed for alkaloid production, and the bottom row are the 
corresponding sclerotia tails. 
 
Resequencing of pseudogene lpsA from C. gigantea 
 Part of the pseudogene lpsA was amplified from C. gigantea genomic DNA using primer 
combination 14 (Table 2) using Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA). 
The fragment contained 743 bp corresponding to nucleotides 3997 to 4739 in the lpsA coding 
sequence and contained the suspected frameshift mutation (GenBank: KY906251). Phusion 
polymerase creates products with blunt ends, so the amplified product was purified (Qiagen) and 
ligated into SmaI-digested pUC18. This construct was then transformed into Escherichia coli, 
plasmid prepped (Qiagen), and sequenced to confirm frameshift mutation found during the 
characterization of C. gigantea’s eas gene cluster (Eurofins, Louisville, KY). 
Preparation of transformation constructs 
Four different constructs were prepared in attempts to accumulate and increase the yield of 
dihydrolysergic acid (Fig. 5). The first construct contained cloA from C. gigantea and a 
bidirectional easA-easG promoter from N. fumigata (Fig. 4, Fig. 5A). The second construct 
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contained an intron free version of cloA from C. gigantea and the bidirectional easA-easG 
promoter from N. fumigata (Fig. 4, Fig. 5B). The third construct contained an intron free version 
of cloA from C. gigantea and a strong gpdA promoter from N. fumigata (Fig. 4, Fig. 5C). The 
fourth construct contained an intron free version of cloA from C. gigantea, the bidirectional easA-
easG promoter from N. fumigata, and easA from C. gigantea (Fig. 4, Fig. 5D). All of the PCR 
amplifications used Phusion high-fidelity polymerase (Thermo Fisher, Waltham, MA) and 
followed the same protocol, with an initial denaturation at 98°C for 30s, followed by 35 cycles of 
98°C (15 s), AT°C (15 s), and 72°C (ET s), and a final extension at 72°C for 60s (AT=annealing 
temperature, ET=extension time, Table 2). The 25 µL PCR mixture contained 11 µL 
distilled/deionized water, 5 µL 5x buffer (100 mM KCl, 20 mM Tris-HCl pH 7.4, 1.5 mM MgCl2), 
4 µL dNTPs (final concentration 200 µM each), 1.25 µL forward primer (final concentration 0.5 
µM), 1.25 µL reverse primer (final concentration 0.5 µM), 2 µL DNA template, and 0.5 units of 
Phusion high-fidelity polymerase. All PCR products were run on agarose gels (0.8% wt/vol) in 0.5 
x TBE (45 mM Tris-Borate, 1 mM EDTA) with ethidium bromide (500 ng/mL). 
C. gigantea cloA construct  
To test whether CloA from C. gigantea would catalyze oxidation of festuclavine, an 
easA/easG promoter-cloA construct was prepared (Fig. 5A), for expression of cloA, in a 
festuclavine-accumulating easM knockout strain of N. fumigata. Primer combination 1 was used 
for amplification of cloA from C. gigantea genomic DNA (Tooley et al., 2006) by PCR (Fig. 4, 
Table 2). The reverse primer in the combination was assembled with an oligonucleotide that 
contained a HindIII restriction site (AAGCTT) near its 5’ end to facilitate cloning of the product 
(Fig. 5A). Primer combination 2 was used for PCR amplification of the easA-easG promoter from 
N. fumigata wild type strain Af293 (Fig. 4, Table 2). The forward primer in the combination was 
assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5’ 
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end (Fig. 5A). The two fragments were joined by adding equimolar amounts of the two initial PCR 
products into a fusion PCR, using primer combination 3 (Fig. 4, Table 2) to form a construct for 
expressing C. gigantea cloA in N. fumigata (Fig. 5A). The easA/easG promoter-cloA construct was 
double-digested with HindIII and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo 
(Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin resistance 
after fungal transformation (Fig. 5A). The plasmid was transformed into E. coli, plasmid prepped 
(Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and DNA 
sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed by 
established methods (Robinson and Panaccione, 2014) into the festuclavine-accumulating easM 
knockout strain of N. fumigata.  
C. gigantea intron free cloA construct  
To test whether an intron free version CloA from C. gigantea would better convert 
festuclavine to dihydrolysergic acid, an easA/easG promoter- intron free cloA construct was 
prepared (Fig. 5B) for expression in the same N. fumigata easM knockout strain. Primer 
combination 4 was used to amplify an intron version of cloA with easA-easG promoter and 3’UTR 
extensions from the 1,524 bp cDNA (see mRNA analysis) (Fig. 4, Table 2). Due to the cDNA not 
having the cloA 3’ UTR, a cloA 3’UTR segment with cloA extension was also individually 
amplified from C. gigantea DNA using primer combination 5 (Fig. 4, Table 2). The reverse primer 
in the combination was assembled with an oligonucleotide that contained an EcoRI restriction site 
(GAATTC) near its 5’ end to facilitate cloning of the product (Fig. 5B). The 5’ UTR was included 
in the bidirectional easA/easG promoter, so it did not need individually amplified. Primer 
combination 2 was used for PCR amplification of the easA-easG promoter with cloA extension 
from N. fumigata wild type strain Af293 (Fig. 4, Table 2). The forward primer in the combination 
was assembled with an oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 
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5’ end (Fig. 5B). The three fragments were joined by adding equimolar amounts into a fusion PCR, 
using primer combination 6 (Fig. 4, Table 2) to form a construct for expressing a fully processed 
version of cloA from C. gigantea in N. fumigata (Fig. 5B). The easA/easG promoter-intron free 
cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaI-digested 
pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for phleomycin 
resistance after fungal transformation (Fig. 5B). The plasmid was transformed into E. coli, plasmid 
prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic digests and 
DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then transformed with 
the same methods, into the festuclavine-accumulating easM KO.  
C. gigantea gpdA promoter construct  
To test whether a stronger promoter from N. fumigata would increase expression of cloA 
in attempts to increase conversion of festuclavine to dihydrolysergic acid, a gpdA promoter- intron 
free cloA construct was prepared (Fig. 5C) for expression in the N. fumigata easM knockout strain. 
Primer combination 7 was used to amplify an intron-free version of cloA with gpdA promoter and 
3’UTR extensions from the 1,524 bp cDNA (see mRNA analysis) (Fig. 4, Table 2). Primer 
combination 8 was used for PCR amplification of the gpdA promoter with cloA extension from N. 
fumigata wild type strain Af293 (Fig. 4, Table 2). No restriction site needed to be assembled to the 
primer, because the sequence already contained an XbaI restriction site (TCTAGA) near its 5’ end 
(Fig. 5C). Equimolar amounts intron-free cloA, gpdA promoter, and 3’UTR (from the previous 
section) were combined in a fusion PCR, using primer combination 9 (Fig. 4, Table 2) to form a 
construct for analyzing the effect of a new, stronger promoter (Fig. 5C). The gpdA promoter-intron 
free cloA construct was double-digested with EcoRI and XbaI, then ligated into EcoRI/XbaI-
digested pBC-phleo (Fungal Genetics Stock Center, Manhattan, KS) to allow for selection for 
phleomycin resistance after fungal transformation (Fig. 5C). The plasmid was transformed into E. 
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coli, plasmid prepped (Qiagen, Gaithersburg, MD), and the construct was confirmed by enzymatic 
digests and DNA sequencing (Eurofins, Louisville, KY). The confirmed plasmid was then 
transformed with the same methods, into the festuclavine-accumulating easM KO strain.  
C. gigantea easA-cloA construct  
To test whether CloA required a species specific EasA to function properly, an easA- 
easA/easG promoter- intron free cloA construct was prepared (Fig. 5D) for expression in an N. 
fumigata easA knockout strain. The bidirectional promoter had to be reamplified using primer 
combination 10, in order to add on easA and cloA extensions (Fig. 4, Table 2).  The easA segment 
with bidirectional promoter extension was amplified from C. gigantea DNA using primer 
combination 11 (Fig. 4, Table 2). The forward primer in the combination was assembled with an 
oligonucleotide that contained an XbaI restriction site (TCTAGA) near its 5’ end to facilitate 
cloning of the product (Fig. 5D). The construct was assembled by adding equimolar amounts easA, 
bidirectional promoter, cloA, and 3’UTR into a fusion PCR, using primer combination 12 (Fig. 4, 
Table 2). The reverse primer for the fusion product was assembled with an oligonucleotide that 
contained a HindIII restriction site (AAGCTT), due to easA from C. gigantea already having an 
EcoRI site in its sequence (Fig. 5D). The easA-cloA construct was double-digested with HindIII 
and XbaI, then ligated into HindIII/XbaI-digested pBC-phleo (Fungal Genetics Stock Center, 
Manhattan, KS) to allow for selection for phleomycin resistance after fungal transformation (Fig. 
5D). The plasmid was transformed into E. coli, plasmid prepped (Qiagen, Gaithersburg, MD), and 
the construct was confirmed by enzymatic digests and DNA sequencing (Eurofins, Louisville, 
KY). The confirmed plasmid was then transformed with the same methods, into an easA KO N. 
fumigata strain.  
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Figure 4: PCR images resulting from the primer combinations in Table 1. Arrows indicate fragments of 
different lengths. Sizes of relevant fragments of BstEII-digested bacteriophage λ DNA is indicated to the 
left of the image. If = intron free. 
 
Figure 5: A) pBC-phleo vector containing the bidirectional easA/easG promoter-cloA construct (Construct 
1). B) pBC-phleo vector containing the bidirectional easA/easG promoter-intron free cloA-3’UTR construct 
(Construct 2). C) pBC-phleo vector containing the gpd promoter-intron free cloA-3’UTR construct. D) 
pBC-phleo vector containing the easA-bidirectional easA/easG promoter-intron free cloA-3’UTR construct. 
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Table 2: Primers and PCR Protocol Information 
 
Fungal Transformation 
The easA/easG promoter-cloA construct, the easA/easG promoter- intron free cloA 
construct, and the gpdA promoter- intron free cloA construct were transformed into an N. fumigata 
easM KO strain, and the easA- easA/easG promoter- intron free cloA construct was transformed 
into an N. fumigata easA KO strain. All constructs were transformed with a phleomycin resistance 
vector containing the gene, ble, from Aspergillus niger.  
Protoplasts were prepared by growing fungal cultures in 50 mL of malt broth at 37 °C with 
shaking at 80 rpm overnight. The broth was discarded and replaced with 15 mL 0.7 M NaCl 
containing 40 mg lysing enzyme (Sigma-Aldrich, St. Louis, MO) and 1 g VinoTaste Pro (Gusmer 
Enterprises Inc., Mountainside, NJ), then shaken for an additional 2 hours at 37 °C and 80 rpm. 
Protoplasts were separated from hyphae by filtering through miracloth and then were pelleted by 
Primer Combination Primer Sequences Product Length (bp)
Annealing 
Temperature (°C) Extension Time (s)
1
GAGTAGGCACTCCGCACCATGTCACTAACATCGTTTTACGCCC + 
CTACAAGCTTCGACTAGGCCACCCACACC
cloA  with bidirectional promoter 
extension 2491 63 75
2
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG + 
GGCGTAAAACGATGTTAGTGACATGGTGCGGAGTGCCTACTC
Bidirectional promoter with cloA 
extension 814 64 30
3
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG + 
CTACAAGCTTCGACTAGGCCACCCACACC
Bidirectional promoter-cloA 
fusion construct 3253 63 100
4
GAGTAGGCACTCCGCACCATGTCACTAACATCGTTTTACGCCC + 
CCGCCGATGTCATACTTCAACTAGTATGTGACTTCAGTCCATC
IF cloA  with bidirectional 
promoter and 3' UTR extensions 1562 63 40
5
GACTGAAGTCACATACTAGTTGAAGTATGACATCGGCG + 
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG 3' UTR + cloA  extension 422 63 20
6
GACCTCTAGACATTGCTTCTAATCCACCAAGTACTTG + 
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG
Bidirectional promoter-cloA -3' 
UTR fusion construct 2713 64 90
7
GTACCAGACGAATCTACACAATGTCACTAACATCGTTTTACGCC + 
CCGCCGATGTCATACTTCAACTAGTATGTGACTTCAGTCCATC
IF cloA  with gpd  promoter and 3' 
UTR extensions 1564 61 40
8
GATTCTAGAAGTCCTGAATAGTAG + 
GGCGTAAAACGATGTTAGTGACATTGTGTAGATTCGTCTGGTAC
gpd  promoter with cloA 
extension 990 64 40
9
GATTCTAGAAGTCCTGAATAGTAG + 
CACAGAATTCGAACTTCTGTGACGTCGCCAGATTG
gpd  promoter-cloA -3'UTR fusion 
construct 2889 60 90
10
GAGTTTGGACGTGGACATTGCTTCTAATCCACCAAGTAC + 
GGCGTAAAACGATGTTAGTGACATGGTGCGGAGTGCCTACTC
Bidirectional promoter with cloA 
and easA  extensions 835 64 30
11
GACATCTAGACTGGCGACGTCACAGAAGTTC + 
GGTGGATTAGAAGCAATGTCCACGTCCAAACTCTTCAAC
easA  with bidirectional promoter 
extension 1322 63 60
12
GACATCTAGACTGGCGACGTCACAGAAGTTC + 
CACAAAGCTTGAACTTCTGTGACGTCGCCAGATTG
easA -bidirectional promoter-cloA-
3'UTR  fusion construct 4054 63 180
13 CTATAGAGTAGGCACTCCGCAC + CTACGCCGACTACTGTTGTCC cloA  internal sequences (cDNA) 1524 -1621 58 45
14 CAGTTCGAGCACGTCTTCTCG + GTGCTCGACAATCATGAGGTC lpsA  internal sequences 743 60 30
18 
 
 
 
centrifugation (3 min at 3,000 × rpm). The protoplasts were washed with 10 mL 0.7 M NaCl and 
5 mL STC (1 M Sorbitol, 1 M Tris (pH = 7.4), 1 M CaCl2), and then resuspended in a final volume 
of STC, so that a 100 µL would have 5x106 protoplasts. A polyethylene glycol (PEG) solution was 
prepared by adding 2 volumes of 37.5% PEG 8000 to 1 volume of PEG amendments (1.8 M KCl, 
150 mM CaCl2, 150 mM Tris (pH = 7.47)) and was added to the protoplast solution in the amount 
of ¼ the final volume that the protoplasts are in. Once the final protoplast solution was prepared, 
125 µL was added to 10 µL of the desired plasmid and incubated on ice for 30 minutes. An 
additional 1 mL of PEG solution was added to the solution and incubated at room temperature for 
20 minutes. The solution was then split across 3 petri dishes (about 365 µL each) and mixed with 
15 mL molten TM102 media (Rykard et al., 1982). Once solidified, an additional layer of molten 
TM102 mixed with 800 µg/mL phleomycin (InvivoGen, San Diego, CA) was added. The plates 
were incubated for 3 days at 37 °C and the blue fungal colonies were replated on malt extract agar 
plates and analyzed by HPLC with fluorescent detection. 
mRNA analysis 
Transformed fungal cultures were grown in 50 mL of malt extract broth in a 250-mL 
Erlenmeyer flask for 1 day at 37°C with shaking at 80 rpm. The produced fungal mat was placed 
in a petri dish and incubated at 37°C for an additional day.  The RNeasy Plant Mini kit (Qiagen, 
Gaithersburg, MD) was used to extract RNA from approximately 80 mg of fungal mat. RNA was 
treated with DNaseI (RNeasy Mini kit) in place of step 6 of the protocol and was reverse 
transcribed with Superscript IV (bypassing the optional RNAse H step). Resulting cDNA was 
diluted 1:10 and amplified by PCR using Phusion high-fidelity DNA polymerase and primer 
combination 13 (Table 2) to test for the presence of cloA. The resulting gel showed two bands, so 
the PCR product was reloaded onto a 0.8% agarose gel and run at 25 V for 4 hours to effectively 
separate these bands, for easier individual purification with Qiaquick columns. Both purified 
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versions of cDNA were ligated into SmaI-digested pUC18 and transformed into E. coli (Fig. 10B), 
in order to have higher concentrations for sequencing, and the resulting plasmids were sent for 
sequencing (Eurofins, Louisville KY). 
Agroclavine feeding study 
The ability of cloA from C. gigantea to utilize both festuclavine and agroclavine as 
precursors was tested by feeding agroclavine to a C. gigantea cloA-bidirectional easA/easG 
promoter transformed N. fumigata strain. Agroclavine is oxidized to lysergic acid by cloA from 
Epichloë sp. Lp1. Twelve cultures of the transformed strain and N. fumigata easM KO strain were 
grown from 60,000 conidia in 200 µL of malt broth. Six cultures of each were supplemented with 
2 µL of agroclavine (10 nmol/µL in 2 µL methanol), whereas the other six cultures were 
supplemented with 2 µL of methanol as a control. Twelve malt extract broth controls were also 
treated with the same supplements. The cultures grew for 1 week in a 37°C incubator. After 
incubation, the cultures were extracted by pulverization with 300 µL HPLC-grade methanol and 
10 glass beads (3-mm-diameter) in a Fastprep 120 (Bio101, Carlsbad, CA) for 30s at 6 m/s. The 
extracted alkaloids were analyzed by HPLC with fluorescence detection for the presence of 
lysergic acid. 
Compartmentalization study 
In order to test whether the substrate and enzymes were being localized in different 
compartments, a compartmentalization study was conducted. Transformed N. fumigata cultures 
were grown in 50 mL of malt extract broth in a 250-mL Erlenmeyer flask for 2 days at 37 °C with 
shaking at 80 rpm for sufficient sporulation. The resulting fungal mat was divided into equal thirds. 
Two of the thirds were homogenized with 200 µL 0.1 M phosphate buffer (pH = 7.6; Kim et al., 
1981), and 0.1 M phosphate buffer supplemented with NADPH (7.5 mg/mL), respectively. The 
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homogenized solutions were transferred to 2-mL microcentrifuge tubes, supplemented with 150 
µL 0.06% Tween 20, and incubated for 2 hours at 23°C. After incubation, equal parts of HPLC-
grade methanol were added to each solution, pelleted by centrifugation, and 90 µL were analyzed 
by HPLC with fluorescence detection. The remaining third was analyzed for ergot alkaloids as the 
control. 
HPLC and LC-MS analyses of the transformants 
Colonies from each transformant were grown on malt agar for 3-5 days. Samples were 
taken with the wide end of a 1,000 µL pipette tip and alkaloids were extracted with 300 µL HPLC-
grade methanol at 23°C for 1 hour. The extracts were pelleted by centrifugation and 20 µL were 
analyzed by reverse-phase high-performance liquid chromatography (HPLC) with fluorescent 
detection.  All samples were separated with a multilinear binary gradient of 5% acetonitrile in 
50mM ammonium acetate to 75% acetonitrile in 50 mM ammonium acetate on a 150-mm by 4.6-
mm C18 column (Phenomenex Prodigy ODS3, 5µm particle size; Torrance, CA; Panaccione et 
al., 2012). A dihydrolysergic acid standard was prepared by dissolving 1 mg ergoloid mesylate 
(Sigma) in 100 µL of 1.2 M NaOH at 75°C for 6 hours, succeeded by the addition of 1.2 M HCl 
to neutralize the standard. 
Festuclavine and dihydrolysergic acid were quantified from all three transformed strains 
derived from easM KO. Festuclavine, dihydrolysergic acid, and fumigaclavine C were quantified 
from the transformed strain derived from easA KO. Agroclavine, lysergic acid, and isolysergic 
acid were quantified from agroclavine fed cultures. All alkaloids were quantified by comparing 
their peak areas to standard curves prepared from dihydroergocristine (for alkaloids fluorescing at 
272 and 372 nm) and ergotamine (for alkaloids fluorescing at 310 and 410 nm). The percent of 
festuclavine converted into dihydrolysergic acid and the percent of agroclavine converted to 
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lysergic acid were calculated and compared by analysis of variance (ANOVA). Statistical analyses 
were conducted with JMP (SAS, Cary, NC). 
For liquid chromatography-mass spectrometry (LC-MS) analysis, week old cultures grown 
on malt extract agar were washed with 4 mL of HPLC-grade methanol. The samples were pelleted 
by centrifugation, concentrated for 4-5 hours in a vacuum centrifuge to a volume between 50-100 
µL, and 10 µL were injected into the LC-MS. The concentrated samples were analyzed by previous 
methods (Ryan et al., 2013) on a Thermo Fisher LCQ DecaXP LC-MS. Dihydrolysergic acid 
samples were analyzed on a Thermo Fisher Q Exactive ultrahigh-performance liquid 
chromatograph mass spectrometer (UHPLC-MS). Analytes were ionized by electrospray 
ionization in positive mode, a spray voltage of 3.5 kV, a capillary temperature of 300°C, and were 
detected by scanning for ions with m/z 200-400. Samples were separated on a 50-mm by 2.1-mm 
Hypersil Gold column (Thermo Fisher, 1.9 µm particle size) in a linear gradient of 5% acetonitrile 
with 0.1% formic acid to 75% acetonitrile with 0.1% formic acid over a 10 minute period with a 
flow rate of 300 µL/min (Ryan et al., 2013). Dihydrolysergic acid has an m/z = 271.2 and was 
eluted at about 7.8 minutes. After an initial full scan of m/z = 200-400, ions of m/z = 271.2 were 
fragmented and analyzed. 
Results 
Function of C. gigantea cloA. A construct for expressing C. gigantea cloA was successfully 
transformed into the N. fumigata easM KO strain. A total of 52 transformants were obtained 
from several transformation experiments, and 33 produced a novel peak that co-eluted with 
dihydrolysergic acid as evidenced by HPLC with fluorescence detection (Fig. 6). No other novel 
peaks of significance were observed in the transformants, but relatively large quantities of 
festuclavine were still observed. The recipient strain, N. fumigata easM KO, accumulated large 
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quantities of festuclavine (data not shown) and nothing that eluted near dihydrolysergic acid 
(Fig. 6) The accumulation of dihydrolysergic acid in the transformants was supported by LC-MS 
analyses in which the cloA-transformed strains produced a parent ion (m/z = 271.2) consistent 
with the [M+H]+ of dihydrolysergic acid (data not shown). The data indicate that CloA catalyzes 
a six-electron oxidation of festuclavine to dihydrolysergic acid as opposed to stopping at 
dihydroelymoclavine (Fig. 2) as expected based on the reported ergot alkaloid profile of C. 
gigantea (Agurell and Ramstad, 1965). The accumulation of dihydrolysergic acid, however, was 
low in comparison to the abundance of festuclavine in the transformed strains. Potential reasons 
for this low accumulation, as well as attempts to increase the yield of dihydrolysergic acid are 
discussed below.   
 
Figure  6: HPLC analysis of transformant strain, dihydrolysergic acid (DHLA) standard, and easM ko host 
strain. 
 
Analysis of the natural ergot alkaloid profile of C. gigantea. Due to C. gigantea catalyzing the 
production of dihydrolysergic acid instead of dihydroelymoclavine, three samples of C. gigantea 
sclerotia (Fig. 3) were obtained from Dr. Carlos De Leon (Monticello, Mexico) and analyzed by 
HPLC (Fig. 7) and LC-MS (Fig. 8) for natural alkaloid production to further investigate its ergot 
alkaloid biosynthetic capacity. Each of the three sclerotia samples accumulated chanoclavine, 
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festuclavine, and dihydrolysergic acid (Fig. 7). This alkaloid profile differed from that reported by 
Agurell and Ramstad (1965), which included chanoclavine, festuclavine, and 
dihydroelymoclavine. Even though a compound with the mass of dihydroelymoclavine was not 
detected it is possible the concentration was below the limit of detection. Another possibility is 
that ergot alkaloid profile varies among isolates of C. gigantea.  
 
Figure 7: Natural ergot alkaloid HPLC chromatogram for C. gigantea sclerotia. DHLA = dihydrolysergic 
acid, C = chanoclavine, F = festuclavine. 
 
 
Figure 8: LC-MS mass spectra for C. gigantea sclerotia compared to DHLA standard. Top left is the parent 
ion (m/z = 271.2) for DHLA in C. gigantea and bottom left is fragment ions (m/z = 253.1, 210.1, 228.1, 
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and 194.2) for DHLA in C. gigantea. This data can be compared to the DHLA standard mass spectra, with 
the top right being the parent ion and the bottom right being the fragment ions. 
 
Characterization of C. gigantea eas gene cluster. The eas gene cluster in the C. gigantea 
genome was characterized to obtain evidence for the type of ergot alkaloids the fungus was 
theoretically capable of producing. The eas cluster (GenBank: KY906251) was studied by 
identifying contigs that contain eas genes by querying the genome’s sequence (Panaccione and 
Schardl, unpublished) with individual eas genes from other Claviceps species. Additional eas 
genes were identified in the originally identified contigs by blastx comparisons of upstream and 
downstream portions of the contigs to the nonredundant nucleotide database at NCBI. The eas 
cluster contained homologs of the following eas genes: dmaW, easF, easC, easE, easD, easA, 
easG, cloA, lpsA, lpsB, and easH (Fig. 9B). The gene cluster indicates the fungus was once 
capable of producing a dihydroergopeptine derivative of dihydrolysergic acid. This hypothesis 
was supported by the observation that the product of the gene cloA from C. gigantea oxidized 
carbon 17 of festuclavine to produce dihydrolysergic acid.   
 
Figure 9: A) Ergot alkaloid synthesis (eas) cluster from wild-type Neosartorya fumigata. B) Predicted eas 
cluster from Claviceps gigantea. Eas genes found in both clusters are grey, whereas genes exclusive to N. 
fumigata are white and genes exclusive to C. gigantea are black. Ψ: pseudogene. 
 
The gene lpsA encodes lysergyl peptide synthetase subunit 1 and acts downstream of CloA 
in the pathway to convert dihydrolysergic acid into ergopeptines. Sequencing of lpsA from C. 
gigantea along with comparison to other sequenced lpsA alleles revealed a frameshift mutation, 
which would almost certainly render the gene nonfunctional. The frameshift is believed to occur 
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between 4345 bp and 4352 bp, since the regions upstream and downstream this frameshift match 
other sequenced lpsA alleles. This frameshift has a span of 8 nucleotides and there should only be 
6 nucleotides in this area to have the correct reading frame. This frameshift mutation results in a 
premature termination codon appearing after amino acid 1458 (4374 bp). The original LpsA 
product should have been 3581 amino acids in length (encoded by 10743 bp), meaning that more 
than half of the coding sequence would not have been translated in the correct reading frame. When 
comparing the C. gigantea lpsA sequence data (GenBank: KY906251) to the Periglandula 
ipomoeae lpsA sequence data (GenBank: AEV21218.1) the altered amino acids are an alanine and 
a valine. The removal of an adenine in the frameshift (located at 4350 bp) in C. gigantea would 
reinstate a valine in the correct position. It does not appear any nucleotide removals in the 
frameshift will reinstate an alanine. However between 4346 bp and 4348 bp there are three 
adenines, making it plausible that one of these nucleotides is the second single nucleotide insertion 
causing the frame shift. The removal of one of these adenines would code for glutamic acid and 
reinstate the correct reading frame. Such a mutation is consistent with the accumulation of 
dihydrolysergic acid as the pathway end product in the C. gigantea sclerotia and it is predicted that 
a functional lpsA homolog would accumulate dihydroergopeptines. It should be noted that the C. 
gigantea genome was obtained from an isolate independent of those analyzed by LC-MS. This 
observation indicates that the dihydrolysergic acid profile is typical among several independent 
isolates of C. gigantea from Mexico. 
Approaches to increase production of dihydrolysergic acid. In order to check for cloA’s 
expression and to see if the introns in cloA were being spliced out correctly, mRNA was extracted 
from the transformants, reverse-transcribed into cDNA, and were sequenced. PCR analyses of 
cDNA prepared from mRNA from the cloA-transformed strain indicated that approximately half 
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of the mRNA was fully processed, whereas the other half was larger than expected (Fig. 10A). 
Sequencing results identified two versions of mRNA, the larger being 1,621 and the smaller being 
1,524 bp. The larger fragment retained 1 out of the 7 introns, specifically intron 4, and the smaller 
fragment was free of introns and likely responsible for the small conversion of dihydrolysergic 
acid (Fig. 10 C). However, the retention of intron 4 results in a frame shift that leads to a stretch 
of 6 incorrect amino acids, followed by a premature termination codon, causing the loss of 288 
amino acids, which presumably renders the resulting protein nonfunctional (Fig. 10D). It was 
plausible that cloA mRNA containing intron 4 could be an issue limiting the production of 
dihydrolysergic acid in the transformed strain.  
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Figure 10: A) cloA cDNA. Arrows indicate fragments of different lengths. Sizes of relevant fragments of 
BstEII-digested bacteriophage λ DNA is indicated to the left of photograph. B) pUC18 containing cloA 
cDNA. C) Genomic cloA with introns and cloA as expressed in transformants with some mRNA containing 
intron 4 (larger band in Fig. 6A) and some with no introns (smaller band in Fig. 6B). D) Amino acid 
sequence for cloA and cloA with intron 4 retained. The amino acid sequence after the 5’-splice junction of 
intron 4 is highlighted yellow. 
In an attempt to increase turnover of festuclavine to dihydrolysergic acid, new versions of 
the cloA expression construct were prepared using the fully processed cDNA as the template. This 
fully processed version of cloA was expressed by the original N. fumigata easA-easG promoter to 
test the effectiveness of removing the intron, and was also expressed by a gpdA promoter to analyze 
if a stronger promoter would increase the accumulation of dihydrolysergic acid. Both constructs 
were analyzed by HPLC and LC-MS for production of dihydrolysergic acid. HPLC data is shown 
for both transformed strains (Fig. 12), LC-MS data is shown for gpdA promoter-cloA transformed 
strain to confirm the product is dihydrolysergic acid (Fig. 11). LC-MS data for intron free cloA is 
not shown. The conversion yields of festuclavine to dihydrolysergic acid were similar, indicating 
the removal of introns (p = 0.58) and a stronger promoter (p = 0.75) did not have a significant 
impact on production of dihydrolysergic acid (Table 3).  Since gpdA promoter-cloA transformed 
strains did not produce larger amounts of dihydrolysergic acid, it did not seem relevant to analyze 
the expression of cloA in these transformants. 
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Figure  11: LC-MS mass spectra for gpd-if cloA transformed strain compared to LC-MS data for DHLA 
standard. Top left shows the parent ion (m/z = 271.2) for transformed strain and bottom left shows fragment 
ions (m/z = 253.1, 210.1, 228.1, and 194.2) for transformed strain. These values can be compared to the 
DHLA standard, with top right showing parent ion (m/z = 271.2) and bottom right showing fragment ions 
(m/z = 253.1, 210.1, 228.1, and 194.2). 
 
In previous studies conducted by Robinson and Panaccione (2014) cloA and easA from 
Epichloë sp. Lp1 were cotransformed into an N. fumigata easA knockout strain. The gene easA 
(isomerase) converted chanoclavine-I-aldehyde to agroclavine, the precursor for Lp1 cloA in their 
study. Since cloA was not transformed individually it was questioned whether CloA requires EasA, 
preferentially from the same source, to function optimally. The gene easA from C. gigantea was 
PCR fused to the free end of the bidirectional N. fumigata easA-easG promoter in the intron-free 
cloA construct. The construct was transformed into an N. fumigata easA KO strain and analyzed 
via HPLC (Fig. 12). The addition of easA (isomerase) from C. gigantea converted chanoclavine 
to our precursor, festuclavine, which was then oxidized to dihydrolysergic acid by cloA (Fig. 12).  
However, the easA KO strain still contained the gene, easM, the product of which converted 
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festuclavine into fumigaclavine B, which was ultimately converted to fumigaclavine C via the N. 
fumigata fumigaclavine pathway (Fig. 12). Since festuclavine was also being converted to 
fumigaclavine C, fumigaclavine C had to be taken into account when calculating the percent 
conversion of dihydrolysergic acid. Even with the diversion of some of the substrate to 
fumigaclavine C, the yield of dihydrolysergic acid increased with the addition of C. gigantea easA 
to the construct (p = 0.01, Table 3). 
 
Figure  12: HPLC analysis of intron free-cloA transformed strain (top), gpd-cloA transformed strain 
(middle), and easA-cloA transformed strain (bottom). All three analyses also include dihydrolysergic acid 
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standard, easM ko host strain (top and middle), and easA ko host strain (bottom). DHLA = dihydrolysergic 
acid, F = festuclavine, C = chanoclavine, Fum C = fumigaclavine C. 
 
Additionally, since it was speculated that CloA was being localized in different subcellular 
locations than the festuclavine substrate, the strain containing cloA expressed from the gpd 
promoter was homogenized and the resulting solutions were incubated with 0.06% Tween 20, and 
either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer supplemented with NAPDH 
(7.5 mg/mL). The homogenized solution was analyzed via HPLC and the quantitative data was 
analyzed using ANOVA and Tukey-Kramer HSD (Table 4). The percent conversion to 
dihydrolysergic acid was only significantly different between the control and the homogenized 
solution incubated with phosphate buffer + NADPH. The other two comparisons were not 
significantly different.   
Table 3: Amount of dihydrolysergic acid converted from festuclavine 
Modified strain Percent conversion to DHLA 
cloA 1.6 ± 0.7 A 
intron-free cloA 2.1 ± 0.5 A 
gpd promoter 1.9 ± 0.5 A 
easA-cloA 4.3 ± 1.5 B 
Values labeled with different capital letters differ significantly in ANOVA (p = 0.01). DHLA = 
dihydrolysergic acid. 
Table 4: Homogenization effect on the production of dihydrolysergic acid 
Homogenization Method Percent conversion to DHLA 
Control 2.6 ± 0.4 A 
Phosphate Buffer 3.7 ± 0.6 AB 
Phosphate Buffer + NADPH 4.6 ± 1.2 B 
Values labeled with different capital letters differ significantly in ANOVA and Tukey-Kramer 
HSD (p = 0.02). DHLA = dihydrolysergic acid. 
Another possible issue that could have been limiting the production of the alkaloid is the 
temperature at which the transformants were grown, since C. gigantea is only found in two regions 
in Mexico, both having cool, humid climates. This made it plausible that the C. gigantea enzymes 
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had a different optimal temperature for activity than N. fumigata. Transformed strains were grown 
at 24 °C, 37 °C, and 50 °C and analyzed by HPLC with fluorescent detection. The optimal 
temperature for C. gigantea gene expression was 37°C, which is the same optimal temperature for 
N. fumigata (Table 5). 
Table 5: Temperature Effect on the Production of Dihydrolysergic Acid 
Temperature Percent conversion to dihydrolysergic acid 
24 °C 1.8 ± 0.2  A 
37 °C 3.6 ± 0.4  B 
50 °C N/A 
Values labeled with different capital letters differ significantly in ANOVA (p = 0.003) 
Substrate specificity of C. gigantea CloA. In order to test substrate specificity of C. gigantea 
CloA, the cloA-transformed strains were fed agroclavine. HPLC analysis showed the agroclavine-
fed transformants accumulated lysergic acid (15.1) and isolysergic acid (21.2) (Fig. 13, Table 6). 
This indicates that CloA from C. gigantea is capable of oxidizing both festuclavine and 
agroclavine as substrates.  
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Figure 13: HPLC analysis of transformed cloA strain fed agroclavine. Top image is chromatogram at 310 
nm/410 nm wavelength and bottom image is chromatogram at 272 nm/372 nm wavelength. LA = lysergic 
acid, Iso-LA = isolysergic acid, Iso-S = isosetoclavine, S = setoclavine, Agro= agroclavine. 
 
Table 6: Amount of lysergic acid converted from agroclavine 
Modified strain Percent conversion to LA 
cloA + agroclavine 0.93 ± 0.13 
easM KO + agroclavine ND 
malt broth + agroclavine ND 
The cloA mutant strain that was fed agroclavine was significantly different from the other trials in 
a Wilcoxon/Kruskal-Wallis test with p = 0.003.  ND = none detected; LA = lysergic acid. 
Discussion 
The expression of CloA in an N. fumigata easM knockout strain altered the fungus to 
imitate the dihydrolysergic acid pathway. Bilovol and Panaccione (2016) synthesized the easM 
KO strain to demonstrate the role of easM in the N. fumigata fumigaclavine pathway. This 
transformant also serves as a transformation recipient to investigate the oxidation of festuclavine 
to dihydroergot alkaloids, based on Barrow et al.’s (1974) finding that festuclavine was a precursor 
to dihydroergot alkaloids in Claviceps africana and by extension Claviceps gigantea. Agurell and 
Ramstad (1965) isolated ergot alkaloids from natural C. gigantea, including festuclavine and 
dihydroelymoclavine. As a result, it was predicted a C. gigantea cloA-transformed strain of N. 
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fumigata would convert festuclavine into dihydroelymoclavine. The mutant strain, however, 
produced dihydrolysergic acid rather than dihydroelymoclavine. These data support the findings 
of Robinson and Panaccione (2014) of CloA catalyzing multiple oxidations. It appears the C. 
gigantea allele of CloA performs a two-electron oxidation of festuclavine to dihydroelymoclavine, 
followed by two sets of two-electron oxidations to convert dihydroelymoclavine to dihydrolysergic 
acid. Also consistent with data reported by Robinson and Panaccione (2014), there was an absence 
of dihydroelymoclavine and other intermediates in our transformants, further indicating that CloA 
binds festuclavine and completes successive oxidations, before releasing dihydrolysergic acid. It 
was also discovered that CloA from C. gigantea was able to utilize both festuclavine and 
agroclavine as substrates, meaning that it is capable of functioning in both dihydrolysergic acid 
and lysergic acid pathways. 
Due to the unexpected production of dihydrolysergic acid instead of dihydroelymoclavine, 
alkaloids from samples of C. gigantea sclerotia were analyzed. Surprisingly, in contrast to the 
findings of Agurell and Ramstad (1965), data from three different sclerotia showed accumulation 
of dihydrolysergic acid, which was not thought to be produced in nature. The data however, 
supported our findings that the product of cloA was responsible for the production of 
dihydrolysergic acid. Additionally, having dihydrolysergic acid as the ergot alkaloid pathway end 
product in the fungus was supported by DNA sequence analysis revealing that the gene encoding 
lysergyl peptide synthetase subunit 1, lpsA, had a frame shift mutation, likely abolishing the genes 
function. It was predicted that the correction of the lpsA mutation would further the dihydrolysergic 
acid pathway to dihydroergosine, as observed by Barrow et al. (1974) for the related fungus C. 
africana. Nevertheless, C. gigantea is the first discovered ergot fungus to have dihydrolysergic 
acid as its pathway end product. 
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Furthermore, after cloA was sequenced from cDNA reverse-transcribed from mRNA from 
the mutant strains, it was discovered that about half of our mRNA was fully processed, containing 
no introns, whereas the other half of mRNA still contained one of the seven introns, specifically 
intron four. This discovery was not surprising, considering some of the cloA introns in C. gigantea 
had unusual 3’ splice junctions, with polyA chains followed by a guanine, instead of the 
conventional YAG. These unusual 3’ splice junctions make it plausible that the host strain, N. 
fumigata, might have problems recognizing the 3’ splice and fail to splice out the intron. An intron-
free version of cloA to see if the removal of the fourth intron would have an effect on the production 
of dihydrolysergic acid. The constructs were successfully transformed and still produced 
dihydrolysergic acid, however there was not a significant difference between the yields in ANOVA 
(p = 0.58). As a result, it could be concluded that the retention of intron four did not have an effect 
on the production of dihydrolysergic acid. 
Additionally, it was questioned whether a stronger promoter would assist in increasing the 
expression of cloA, hopefully increasing the turnover of dihydrolysergic acid. The intron-free 
version of cloA was expressed from an N. fumigata glyceraldehyde-3-phospate dehydrogenase 
(gpdA) promoter, which was assumed to be stronger than the N. fumigata easA-easG bidirectional 
promoter, due to its original role for expressing a gene important for glycolysis. These mutant 
strains also produced dihydrolysergic acid, however there was not a significant difference between 
the yield produced by this strain compared yield produced by the original strain in ANOVA (p = 
0.75). As a result, it could be concluded that a different promoter did not have a significant effect 
on the production of dihydrolysergic acid. 
Moreover, since Robinson and Panaccione (2014) coexpressed CloA with the 
oxidoreductase, EasA from the same organism, it was questioned whether CloA functionally 
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required coexpression with a species specific EasA to more efficiently generate dihydrolysergic 
acid. The coexpression of cloA and easA both from C. gigantea in an N. fumigata easA KO 
produced two-fold more dihydrolysergic acid (p = 0.006), indicating that the two enzymes may 
interact in the pathway and that cloA from C. gigantea may function better with easA from C. 
gigantea rather than easA from N. fumigata. This yield was significantly different from the original 
yield in ANOVA, however it is important to note that the overall yield was still low. 
Similarly, it was also predicted that the enzymes and substrates may be localized in separate 
compartments. To test this, the transformants were homogenized and incubated with tween, and 
either 0.1 M phosphate buffer (pH = 7.6) or 0.1 M phosphate buffer (pH = 7.6) supplemented with 
NADPH (7.5 mg/mL). These homogenized solution incubated with 0.1 M phosphate buffer 
supplemented with NADPH was significantly different in production of dihydrolysergic acid from 
the control in ANOVA (p = 0.02). However, it cannot be concluded if the enzymes may be 
localized in a separate compartment than the substrate or if the addition of NADPH helped in the 
production. It is also important to note that the overall yield from this experiment was also low. 
Another possibility that could be effecting the expression of cloA and/or the turnover of 
dihydrolysergic acid is the random integration of the constructs into the genome, as a result of our 
traditional transformation methods. Depending on where the construct is integrated it could be 
highly expressed, lowly expressed, or not even expressed at all. Multiple transformants were 
analyzed and their conversions of dihydrolysergic acid were averaged in attempts to minimize this 
issue. 
Lastly, it was questioned whether cloA from C. gigantea could oxidize substrates other 
than festuclavine. Agroclavine was fed to the mutant strains and analyzed the ergot alkaloids 
secreted into the media by HPLC. As a result, it was discovered that cloA from C. gigantea can 
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oxidize agroclavine to lysergic acid, the same as cloA from Epichloë sp. Lp1 in Robinson and 
Panaccione’s study (2014). This means that our allele of cloA is capable of oxidizing both 
festuclavine and agroclavine, making it functional in both the dihydrolysergic acid pathway and 
in the lysergic acid pathway. 
Overall, the potential of the gene cloA from C. gigantea was unlocked to produce the 
pharmaceutically important ergot alkaloid dihydrolysergic acid by genetically engineering a strain 
of N. fumigata. Several significant pharmaceuticals, such as nicergoline (Sermion) and pergolide 
(Permax), are currently being derived from lysergic acid, however semisynthetic derivation from 
dihydroelymoclavine and/or dihydrolysergic acid would be more efficient. These drugs are 
pharmaceutically relevant due to their structural similarities to neurotransmitters, allowing them 
to treat cognitive and neurological disorders, such as migraines, dementia, Alzheimer’s, and 
Parkinson’s disease (Morren and Galvez-Jimenez 2010;Baskys and Hou 2007;Winblad et al. 
2007;Perez-Lloret and Rascol 2010). The generation of dihydrolysergic acid in such a fast-growing 
organism would have a tremendous impact on drug modification and turnover for these 
pharmaceuticals, when an alternative starting material is created. Additionally, understanding the 
genes in the pathway could assist in producing libraries of ergot alkaloid derivatives with altered 
pharmacology. 
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